Bevacizumab and Olaparib

About

Membership operator: AND

Therapies: 2

Therapies

Bevacizumab (tx:ncit:C2039)

Olaparib (tx:ncit:C71721)

View API

Therapeutic response

Precision oncology relationships for therapeutic response involving this therapy group.

Organizations
Biomarkers
Cancer types
Therapies
Organizations Biomarkers Cancer types Therapies
FDA (2) HC (1) BRCA1 oncogenic variants Ovarian Epithelial Tumor Bevacizumab, Olaparib
FDA (2) HC (1) BRCA1 pathogenic variants Ovarian Epithelial Tumor Bevacizumab, Olaparib
FDA (2) HC (1) BRCA2 oncogenic variants Ovarian Epithelial Tumor Bevacizumab, Olaparib
FDA (2) HC (1) BRCA2 pathogenic variants Ovarian Epithelial Tumor Bevacizumab, Olaparib
FDA (2) HRD Ovarian Epithelial Tumor Bevacizumab, Olaparib
FDA (2) HC (1) BRCA1 oncogenic variants High-Grade Serous Fallopian Tube Cancer Bevacizumab, Olaparib
FDA (2) HC (1) BRCA1 pathogenic variants High-Grade Serous Fallopian Tube Cancer Bevacizumab, Olaparib
FDA (2) HC (1) BRCA2 oncogenic variants High-Grade Serous Fallopian Tube Cancer Bevacizumab, Olaparib
FDA (2) HC (1) BRCA2 pathogenic variants High-Grade Serous Fallopian Tube Cancer Bevacizumab, Olaparib
FDA (2) HRD High-Grade Serous Fallopian Tube Cancer Bevacizumab, Olaparib
FDA (2) HC (1) BRCA1 oncogenic variants Peritoneal Serous Carcinoma Bevacizumab, Olaparib
FDA (2) HC (1) BRCA1 pathogenic variants Peritoneal Serous Carcinoma Bevacizumab, Olaparib
FDA (2) HC (1) BRCA2 oncogenic variants Peritoneal Serous Carcinoma Bevacizumab, Olaparib
FDA (2) HC (1) BRCA2 pathogenic variants Peritoneal Serous Carcinoma Bevacizumab, Olaparib
FDA (2) HRD Peritoneal Serous Carcinoma Bevacizumab, Olaparib